The FDA told Amgen to test whether a quarter-dose of a lung cancer drug worked as well as Amgen’s recommended amount. It did, with fewer side effects. But cutting the dose means less revenue.
More than 25 million Americans — including 21 million adults — have asthma, a chronic disease that makes it hard to breathe and, in rare cases, can be fatal.